Compare Johnson & Johnson (JNJ) vs Bristol-Myers Squibb Company (BMY) Stock

Johnson & Johnson (JNJ) offers the better valuation at 42.9x trailing P/E (21.5x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 10.0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +70.8%, compared to +19.7% for Bristol-Myers Squibb Company (BMY). A $10,000 investment in JNJ five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: JNJ returned +175.7% versus BMY's +32.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.06β versus Bristol-Myers Squibb Company's 0.35β — meaning BMY is approximately 526% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.8% net margin versus -18.5% for Bristol-Myers Squibb Company — meaning it keeps 15.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24.9% versus 20.0% for BMY. At the gross margin level — before operating expenses — JNJ leads at 69.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 10.0x forward P/E versus 21.5x for Johnson & Johnson — 11.5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMY: -0.2% to $62.27.

All stocks in this comparison pay dividends. Bristol-Myers Squibb Company (BMY) offers the highest yield at 3.8%, versus 2.0% for Johnson & Johnson (JNJ).

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.06), 2.0% yield, +175.7% 10Y return). Both have compounded well over 10 years (JNJ: +175.7%, BMY: +32.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: JNJ is a large-cap quality compounder stock; BMY is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.